Development of [²¹¹At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.

ABSTRACT: Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing interest are alpha-particle-emitting radionuclides such as astatine-211 (²¹¹At) as they deliver large amounts of radiation over just a few cell diameters, enabling efficient and selective target cell kill. Here, we developed ²¹¹At-based RIT targeting CD123, an antigen widely displayed on acute leukemia and MDS cells including underlying neoplastic stem cells. We generated and characterized new murine monoclonal antibodies (mAbs) specific for human CD123 and selected four, all of which were internalized by CD123+ target cells, for further characterization. All mAbs could be conjugated to a boron cage, isothiocyanatophenethyl

SUBMITTER: Laszlo GS 

PROVIDER: S-EPMC9177726 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature